SYK Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 8.48% compared to Stryker's net margin of 12.41%. Stryker's return on equity of 15.22% beat Boston Scientific's return on equity of 8.96%.

Stryker has a consensus price target of $423.40, signalling upside risk potential of 15.01%. On the other hand Boston Scientific has an analysts' consensus of $115.46 which suggests that it could grow by 17.22%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Boston Scientific quarterly revenues of $4.6B. Stryker's net income of $546M is lower than Boston Scientific's net income of $566M. Notably, Stryker's price-to-earnings ratio is 47.44x while Boston Scientific's PE ratio is 78.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 8.74x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 8.48% compared to Stryker's net margin of 28.41%. Stryker's return on equity of 15.22% beat Intuitive Surgical's return on equity of 15.6%.

Stryker has a consensus price target of $423.40, signalling upside risk potential of 15.01%. On the other hand Intuitive Surgical has an analysts' consensus of $622.28 which suggests that it could grow by 25.81%. Given that Intuitive Surgical has higher upside potential than Stryker, analysts believe Intuitive Surgical is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Stryker's net income of $546M is lower than Intuitive Surgical's net income of $685.7M. Notably, Stryker's price-to-earnings ratio is 47.44x while Intuitive Surgical's PE ratio is 77.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 21.44x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Pro-Dex has a net margin of 8.48% compared to Stryker's net margin of 12.15%. Stryker's return on equity of 15.22% beat Pro-Dex's return on equity of 21.59%.

Stryker has a consensus price target of $423.40, signalling upside risk potential of 15.01%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 6.63%. Given that Stryker has higher upside potential than Pro-Dex, analysts believe Stryker is more attractive than Pro-Dex.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison Pro-Dex has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.026%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Pro-Dex quarterly revenues of $16.8M. Stryker's net income of $546M is higher than Pro-Dex's net income of $2M. Notably, Stryker's price-to-earnings ratio is 47.44x while Pro-Dex's PE ratio is 25.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 2.83x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 8.48% compared to Stryker's net margin of 16.85%. Stryker's return on equity of 15.22% beat Insulet's return on equity of 43.11%.

Stryker has a consensus price target of $423.40, signalling upside risk potential of 15.01%. On the other hand Insulet has an analysts' consensus of $314.66 which suggests that it could grow by 22.53%. Given that Insulet has higher upside potential than Stryker, analysts believe Insulet is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.89%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Insulet quarterly revenues of $597.5M. Stryker's net income of $546M is higher than Insulet's net income of $100.7M. Notably, Stryker's price-to-earnings ratio is 47.44x while Insulet's PE ratio is 44.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.28x versus 9.16x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.